Alaunos Therapeutics completes acquisition of Velaris Therapeutics
Alaunos completed its acquisition of privately held Velaris Therapeutics, adding a pipeline targeting pulmonary arterial hypertension and related cardiopulmonary diseases. The deal brings ActRII-Fc ligand traps and complementary biologics aimed at correcting signaling imbalances linked to pulmonary vascular remodeling.